BioSpace News Archive

OliX Pharmaceuticals to accelerate the development of effective targeted therapy for liver diseases using AM Chemical’s GalNAc-conjugation technology SUWON, Republic of Korea, March 30, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc . (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has signed an exclusive worldwide licensing agreement with AM Chemicals (AMC) for the rights to patents and know-how encompassing the technology to conjugate N-

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will report its 2019 Fourth Quarter and Full-Year Financial Results on Monday, March 30, 2020 after the close of trading on NASDAQ.

CHASE Clinical Trial. On September 23, 2019, the Company announced findings from the pre-specified interim review of its ongoing CHASE clinical trial.

Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson ,

EUA Application Follows Completion of Test Validation with Patient Samples by Physician-Scientists at UC San Diego

Article reviews mechanisms of action (MOA) of medications used in the treatment of patients with narcolepsy and clinical implications

Following distribution agreements for Russia, Ecuador, Panama, Romania and Moldova, PreCheck’s eleven combined distribution territories have an aggregate population of 298 million

Promethera ® Announces Changes in Management Team

NDA submission based on previous pivotal trial data and a phase 2 study in Japan in patients with certain relapsed/refractory B-cell lymphomas

Aptorum Group Limited announced that it is initiating an additional research and development project targeting the coronavirus group and has completed initial screening under the Smart-ACT™ platform, a repurposed and new drug discovery platform, to select, out of more than 2,600 approved small drug molecules, at least 3 potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19.